surmount studies tirzepatide surmount-1 trial obesity without diabetes Gastrointestinal tolerability and weight reduction associated with in adults surmount-1 trial tirzepatide non-diabetic obesity

The metabolic health benefits of these medications extend well beyond weight loss

Initially, some patients received coverage for these medications, but fewer and fewer patients are getting coverage for them as time goes on

Some patients mistakenly believe that cloudy appearance is the only sign of degradation, but peptide breakdown often occurs without visible changes

Fortunately, there are simple yet effective ways to mitigate these potential discomforts

Why did I suddenly lose taste

Discontinuation rates due to adverse events in TRIUMPH-3 were 9.8% (9 mg) and 13.5% (12 mg) with retatrutide, compared with 4.8% for placebo